Skip to main content

Table 2 Secondary outcomes

From: Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE® CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial

Parameter Method of analysis
Coll2-1 Decrease between inclusion (D-10) and D30 or D180
Lequesne index (LI) Decrease between inclusion visit (D-10) and further visits
Global assessment of pain Visual analog scale (VAS, 0–100 mm) between inclusion visit (D-10) and further visits
OMERACT/OARSI set of criteria Percentage of responders at D90 and D180
Acetaminophen and NSAID consumption Number of patients that required at least once rescue medication during the study
Patient’s global assessment of the disease activity 11 points Likert scale ranging of 0 (low active disease) to 10 (maximum activity)
  1. Abbreviations: OMERACT Outcome Measures in Rheumatology, OARSI Osteoarthritis Research Society International, D-10 10 days before injection, D30, D90, D180 respectively 30, 90, and 180 days following injection